Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Duration depends on goals, hormone levels, and individual response
doi: 10.1128/MCB.23.15.5293-5300.2003 101
352 Elacestrant has emerged as the first FDA-approved oral estrogen receptor antagonist for ESR1 -mutant patients, owing to substantial improvements in progression-free survival (PFS) observed during the EMERALD phase 3 trial in the ESR1 -mutant population
Conflict of interest The authors declare that this review was prepared in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
What to expect during the washout period As your previous medication clears from your system, several physiological changes may occur
US$ 20.55
US$ 28.72
US$ 23.47
